Business Wire

FL-I-SQUARED-CAPITAL

19.5.2023 14:01:35 CEST | Business Wire | Press release

Share
I Squared Capital Appoints Gautam Bhandari as Global Chief Investment Officer

I Squared Capital, a leading global infrastructure investment manager, today announced that Gautam Bhandari, co-founder and Managing Partner, has been appointed as I Squared Capital’s Global Chief Investment Officer, responsible for leading the firm’s global investment strategy in close collaboration with founder, Chairman and Managing Partner Sadek Wahba. This new appointment is part of additional changes to its management and governance structure that will build on the firm’s success to further institutionalize I Squared Capital for the coming decade and beyond.

In addition, I Squared Capital has named Mohamed Adel El-Gazzar and Harsh Agrawal as Senior Partners and members of the Executive Committee of the firm. The newly formed Executive Committee will lead the strategic development of the firm.

“These structural enhancements come at an important moment for I Squared,” said Dr. Wahba. “As we reflect on the tremendous success of the past decade, we are taking steps to further institutionalize our firm and ensure that we are well positioned to capitalize on the unique opportunities of the next decade and beyond.”

“As I Squared continues to grow, I look forward to working with the Executive Committee to ensure that new fundraises and investments are calibrated to the firm’s disciplined approach of investing in and building high-quality, world-class businesses for the future,” said Dr. Bhandari. “We believe the demand for infrastructure will continue to grow globally as many capital-intensive sectors of the economy, such as energy, telecommunications, and transportation urgently need to modernize and also address the ever-increasing demand for sustainable infrastructure.”

Dr. Bhandari, co-founder and Managing Partner, has been a member of the Investment Committees of I Squared Capital since inception and he chairs the boards of several I Squared Capital portfolio companies globally. Prior to I Squared Capital, he was a Managing Director at Morgan Stanley where, for over ten years, he worked on infrastructure investments, as well as banking and capital markets. He holds a Ph.D. in Chemistry from the University of Delaware, where he was the University Merit Fellow and recipient of the Joel L. Silver Award for the best doctoral dissertation work, and an MBA in Finance from the Stern School of Business at New York University, where he was an Amerada Hess Merit Scholar.

Furthermore, I Squared Capital has formed an Operating Committee to manage the operations of the firm and to support the continued global growth of the platform. The Operating Committee will consist of the firm’s Partners along with a broader group of senior executives of I Squared Capital. The global platform has grown to over 215 employees, having hired 81 professionals since the start of 2022.

In parallel, Adil Rahmathulla, Managing Partner, will be transitioning from his role at I Squared Capital over the coming year to pursue other opportunities. He will remain on the firm’s Investment Committees ahead of his eventual departure from the firm in June 2024.

Dr. Wahba and Dr. Bhandari stated, “We are extremely grateful to Adil for the vital role he has played in co-founding and growing I Squared Capital. He has been a great partner, and we are pleased he will continue to work closely with us over the coming year. We are confident he will be successful in his future endeavors, and we wish him all the best.”

“It has been a privilege to work alongside Sadek, Gautam and the I Squared Capital team to contribute to the firm’s growth into one of the world’s leading infrastructure investors,” said Mr. Rahmathulla. “I am immensely proud of what we have achieved over the last decade and am excited to watch and support the firm’s continued success. I am grateful to Sadek and Gautam for their partnership and friendship, and I look forward to continuing my journey as an investor and entrepreneur in the years ahead.”

As part of these changes, over twenty senior employees of the firm, in addition to the existing shareholders, will be investing their own capital into the equity ownership of I Squared Capital, further broadening the firm’s shareholder base and strengthening alignment of interests. No financial details will be disclosed.

About I Squared Capital

I Squared Capital is an independent global infrastructure manager with over $37 billion in assets under management focused on investing in North America, Europe, Asia, and Latin America. Headquartered in Miami, the firm has more than 215 professionals across its offices in Miami, Hong Kong, London, New Delhi, Singapore, Taipei, and Sydney. I Squared Capital has invested in a diverse portfolio of 77 companies in 59 countries with over 31,000 employees across the utilities, energy, digital infrastructure, transport, environmental infrastructure, and social infrastructure sectors providing essential services to millions of people around the world.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005039/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye